Elevated interleukin-6 levels predict short-term flare in systemic lupus erythematosus - Takeaways - MDSpire

Elevated interleukin-6 levels predict short-term flare in systemic lupus erythematosus

  • By

  • Borja del Carmelo Gracia Tello

  • José Miguel García-Bruñén

  • Luis Corredor

  • Natalia Allue Fantova

  • Eva Ma Calvo Beguería

  • Rubén García-Muñío

  • Laura Pérez Abad

  • Jimena Aramburu Llorente

  • Beatriz Martinez Muriel

  • Paula Vidales Miguélez

  • Roxanna Alexandra Morante Mendoza

  • Julia Martínez Artigot

  • Noelia Chicano Nieto

  • Jorge Álvarez Troncoso

  • Luis Martinez-Lostao

  • Adela Marín Ballvé

  • May 8, 2026

  • 0 min

Share

  • 1

    Increased interleukin-6 (IL-6) levels are associated with short-term flares in systemic lupus erythematosus (SLE).

  • 2

    A study of 188 SLE patients found that 48% had IL-6 levels exceeding 5 pg/mL during follow-up assessments.

  • 3

    Higher IL-6 concentrations correlated with a significantly shorter time to the next SLE flare, reducing the interval by 10 months.

  • 4

    IL-6 levels predicted the occurrence of various SLE manifestations, including arthritis, nephritis, and serositis.

  • 5

    IL-6 demonstrated superior predictive capability compared to traditional biomarkers like anti-dsDNA and complement components.

Original Source(s)

Elevated interleukin-6 levels predict short-term flare in systemic lupus erythematosus

  • by Borja del Carmelo Gracia Tello, José Miguel García-Bruñén, Luis Corredor, Natalia Allue Fantova, Eva Ma Calvo Beguería, Rubén García-Muñío, Laura Pérez Abad, Jimena Aramburu Llorente, Beatriz Martinez Muriel, Paula Vidales Miguélez, Roxanna Alexandra Morante Mendoza, Julia Martínez Artigot, Noelia Chicano Nieto, Jorge Álvarez Troncoso, Luis Martinez-Lostao, Adela Marín Ballvé

  • May 8, 2026

Related Content

Clinical characteristics and risk factors of protein-losing enteropathy: a retrospective study

FDA Reshapes Drug Testing Approach

The agency outlined early regulatory actions supporting nonanimal methods, including draft guidance, artificial intelligence tools, and expanded use of human-relevant data models.

Using objective measures of physical activity, sleep, and breathing for disease profiling of patients with systemic lupus erythematosus and Sjögren's disease